Aurinia Pharmaceuticals Inc.
AUPH
$13.17
$1.058.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 70.01M | 62.47M | 59.87M | 67.77M | 57.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 70.01M | 62.47M | 59.87M | 67.77M | 57.19M |
| Cost of Revenue | 14.55M | 14.32M | 13.66M | 9.08M | 12.99M |
| Gross Profit | 55.46M | 48.15M | 46.21M | 58.69M | 44.20M |
| SG&A Expenses | 26.02M | 20.34M | 37.03M | 42.37M | 44.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 9.25M | 4.43M | 1.39M | 4.57M | -290.00K |
| Total Operating Expenses | 49.81M | 39.09M | 52.09M | 56.02M | 57.63M |
| Operating Income | 20.20M | 23.38M | 7.78M | 11.75M | -441.00K |
| Income Before Tax | 22.16M | 24.35M | 1.17M | 14.81M | 1.48M |
| Income Tax Expenses | 643.00K | 1.01M | -256.00K | 457.00K | 756.00K |
| Earnings from Continuing Operations | 21.51M | 23.34M | 1.43M | 14.35M | 722.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.51M | 23.34M | 1.43M | 14.35M | 722.00K |
| EBIT | 20.20M | 23.38M | 7.78M | 11.75M | -441.00K |
| EBITDA | 25.06M | 28.24M | 12.64M | 16.64M | 4.40M |
| EPS Basic | 0.16 | 0.17 | 0.01 | 0.10 | 0.01 |
| Normalized Basic EPS | 0.10 | 0.12 | 0.07 | 0.06 | 0.01 |
| EPS Diluted | 0.16 | 0.16 | 0.01 | 0.10 | 0.01 |
| Normalized Diluted EPS | 0.10 | 0.11 | 0.07 | 0.06 | 0.01 |
| Average Basic Shares Outstanding | 134.87M | 138.92M | 142.18M | 143.05M | 143.33M |
| Average Diluted Shares Outstanding | 137.53M | 143.20M | 147.68M | 145.65M | 144.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |